Marshall Wace North America’s Cardlytics CDLX Stock Holding History

Marshall Wace North America’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,457	Closed	-$3.12M	–	1455
2021 Q2	$3.12M	Sell	2,457 -735	-23%	-$829K	0.01%	678
2021 Q1	$3.5M	Buy	+3,192	New	+$4.21M	0.01%	654
2019 Q1	–	Sell	-93	Closed	-$10K	–	1588
2018 Q4	$10K	Buy	+93	New	+$15.7K	﹤0.01%	1418
2018 Q3	–	Sell	-1,170	Closed	-$255K	–	964
2018 Q2	$255K	Sell	1,170 -4,422	-79%	-$818K	﹤0.01%	1217
2018 Q1	$818K	Buy	+5,592	New	+$946K	﹤0.01%	1046

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Marshall Wace North America's CDLX Position: Q3 2021 in Review

Marshall Wace North America sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 2,457 shares — an estimated $3.12M sold.

Marshall Wace North America first reported a position in CDLX in Q1 2018 and held it in 5 quarters. The position peaked at $3.5M in Q1 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

Marshall Wace North America reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 2,457 Cardlytics shares in Q3 2021, an estimated $3.12M.
Marshall Wace North America first reported a position in Cardlytics in Q1 2018 and held it in 5 quarters.
Marshall Wace North America's Cardlytics position peaked at $3.5M in Q1 2021.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.